Livatag ® is a treatment shown in nanoparticles doxorubicin in therapy refraktär provide cells against chemotherapy. Livatag ® has been granted an orphan drug status in Europe and the United States. The product is described in patients with advanced hepatocellular carcinoma, is evaluated highly therapy refraktär to a chemotherapy (via hepatic intra-arterial route). Hepatocellular carcinoma (primary liver cancer) is the third cause of cancer mortality in the world.
BioAlliance Pharma phase II follow-up results showed a median survival of 32 months for Livatag ® group, compared to 15 months for patients always current best of care (TACE Transarterial Chemoembolization with a cytotoxic drug). This significant 17 months difference in median survival is the basis for strong interest in the product while on clinical hold.
BioAlliance Pharma is looking forward to the successful development of the proprietary new intravenous administration of Livatag ® in animal models, validated that reduces acute pulmonary adverse events, which led to the clinical hold. Livatag ® new administration ground together with the survival observed is the French Agency for drug of Q2 2011 forwarded. The last complete data in a specialized international Congress intends communicate the society.
"We believe that these new achievements are paving the way for a constructive dialogue with the health authorities, taking into account resistant benefit the impressive survival in this serious disease." "Livatag ® is perfectly in line with our orphan product strategy and could be significant benefits for the company catalyst," said Dominique Costantini, CEO of BioAlliance Pharma.
Source:
BioAlliance Pharma
Posts
0 comments: on "Livatag(R) (doxorubicin Transdrug ™) Follow-Up shows significant survival increase in advanced hepatocellular carcinoma patients"
Post a Comment